Izidlo ze-Ketogenic ze-ADHD
Ngaba i-Keto inokunceda i-ADHD?
Ukutya kwe-Ketogenic kunokunceda i-ADHD ngokunyanga iindawo ezininzi ze-pathology ezichongiweyo njengebangela iimpawu. Ezi ndawo ziquka i-glucose hypometabolism, ukungalingani kwe-neurotransmitter, i-brain-derived neurotrophic factor, ukuvuvukala, kunye noxinzelelo lwe-oxidative. Ukutya kwe-ketogenic eyenziwe kakuhle kunokuphucula imeko yezondlo kunye nokunyanga ukusilela kwe-cofactor okubonwa ngabantu be-ADHD.
Isiqulatho
intshayelelo
I-Attention Deficit Disorder (ADD) kunye ne-Attention Deficit Hyperactivity Disorder (ADHD) zibonwa ziphenjelelwa ngokuyintloko lufuzo kwi-80% yamatyala. Noko ke, njengakuyo yonke imizila yemfuza, imekobume evula ize icime ezo mizila yemfuza yeyona nto inamandla ebizwa ngokuba yiepigenetics. Kwaye indlela yokuphila, ukutya, ukuzivocavoca, ukukhanya kwelanga, indawo ezixinzelelekileyo, i-toxins zonke zinyanzelisa i-epigenetic factor. Oku kuthetha ukuba banokwenza ukuba eminye imizila yemfuza ichaze ngakumbi kwaye abanye baziveza kancinci. Ke into efana ne-ketogenic diet, eyona nto inamandla yokutya kunye nendlela yokuphila ye-epigenetic factor, inokunceda ukunciphisa okanye ukunciphisa ezinye zeempawu ze-ADHD.
Kodwa mandicacise. Akukho RCTs ebonisa ukuba ukutya kwe-ketogenic kunceda kwi-ADHD kunye ne-ADD. Kodwa kusenokwenzeka ukuba ziyeza kungekudala. Njengoko ubungqina be-anecdotal buqhubeka nokunyuka, umdla kunye nenkxaso-mali kwii-RCTs zinokwenzeka. Nangona singasoze sizibone zisenziwa ngamandla njengoko besiya kwenza kumayeza anengeniso ephezulu. Sekunjalo, ukuba ukhangela kwi-Reddit ye-ADHD, i-ADD, kunye ne-Keto, ufumana abantu abaninzi babelana ngamabali abo ukuba ukutya kwe-ketogenic kuye kwabanceda. Unokufunda ezinye zazo Apha. Kwaye njengoko abaninzi bekhe babuza ngaphambili, ukhe weza kweli phepha ubuza umbuzo "Ngaba i-keto inokunceda i-ADHD?"
Esi sithuba sebhlog siya kuphonononga ezinye zeendlela apho ukutya kwe-ketogenic kunokunceda ukuphatha ezinye zeempawu ze-ADHD kunye ne-ADD. Kwizithuba zangaphambili, sihlolisise indlela ukutya kwe-ketogenic kuphatha ngayo le mimandla ilandelayo engaphantsi kwe-pathologies, ngokubanzi. Unokufunda ezi zithuba zincinci kodwa zinolwazi Apha, Apha, yaye Apha. Kule post, siza kuphonononga ezi ndawo zine ze-pathology ezibonwa kwi-ADHD kunye ne-ADD kwaye sihlolisise ukuba ukutya kwe-ketogenic kunokuphucula iimpawu ezinokuvela kule mimandla yokungasebenzi:
- IGlucose Hypometabolism
- Neurotransmitter Ukungalingani
- Ukuvutha
- Uxinzelelo oluxhasayo
Kule post yebhlog, ndiza kwandisa ezi ndawo zonyango ezinokubakho ngaphandle kancinci ukubandakanya ulwazi olubanzi kakhulu malunga ne-brain-derived neurotrophic factor (BDNF) kunye nendima yesistim somzimba kwi-ADHD/ADD. Zombini zizinto ezifanelekileyo zokuphononongwa njengoko uzama ukuphendula ukuba ukutya kwe-keto kunokunceda nge-ADHD kunye ne-ADD.
Andiyi kungena kwiimpawu okanye kwiikhrayitheriya zokuxilonga ze-ADHD ngokweenkcukacha kule bhlog. Ayenzelwanga ukuba ibe lulwazi ngolo hlobo, kwaye kukho amanqaku amaninzi kwi-intanethi anika olu lwazi. Ukuba ufumene le bhlog, kungenxa yokuba uyazi ukuba yintoni i-ADHD kunye ne-ADD, kwaye unokufuna iindlela zokunyanga iimpawu zakho okanye umntu omthandayo.
Usenokuba uyazibuza ukuba unokunyanga i-ADHD ngaphandle kwamayeza avuselelayo. Okanye unokuba uhlola ukuba ngaba okanye ukungamkeli ukutya kwe-ketogenic kunokuvumela ukuba udinge amayeza amancinci avuselelayo. Amayeza amancinci anokuba luncedo, ngakumbi kuba amayeza engqondo aphelisa izondlo.
Amayeza engqondo, njengalawo asetyenziselwa ukunyanga i-ADHD kunye ne-ADD, aphelisa ezi zondlo zilandelayo:
- Magnesium
- intsimbi
- Ifayile
- I-Omega 3s
- B1, B2, B3, B6 kunye neB12
- Izinki
- CoQ10
Ukuncipha kwe-micronutrient ekusetyenzisweni kwamayeza kudityaniswa kukuthomalaliswa kokutya okufunyenwe nge-ADHD kunye namayeza e-ADD. Ukunciphisa umnqweno wokutya okubangelwa kukusetyenziswa kwamayeza kunokubangela ukuba wena okanye umntu omthandayo ungatyi ngokwaneleyo ukuzalisa oku kuncipha. Ungafuna ukukwazi ukuthatha amayeza amancinci avuselelayo ngenxa yesi sizathu kuphela. Olu luhlu lungasentla lokunciphisa izondlo lufanelekile kwaye luchaphazela ngokuthe ngqo indlela ingqondo yakho enokusebenza ngayo. Nokuba ubuchopho bakho bunokutshisa amandla okuthetha phakathi kwee-neurotransmitters, ukunciphisa ukudumba, kunye nokuzilungisa zonke zixhomekeke kwisixa esaneleyo sezo zondlo zidweliswe ngasentla.
Okuhlekisayo, ndiyazi.
Usenokuba ufunda le bhlog ngenxa yokuba une-ADHD okanye i-ADD kuphela, okanye unokuba ufunda le bhlog kuba une-ADHD kunye nolunye ukuphazamiseka kwe-comorbid ofuna ukukhululeka kuyo. Uninzi lwabantu abadala abane-ADHD bathwaxwa yimeko ye-comorbid, ebandakanya:
- ukuphazamiseka kobuntu bomntu (14-24%)
- Qaphela: ebantwaneni olu xilongo luhlala luyi-Oppositional-Defiant Disorder. Ukuba iyaqhubeka idlule iminyaka eyi-18, uxilongo lutshintshela kwi-PD ye-antisocial
- ukuphazamiseka kobuntu bomda (14%)
- ukuphazamiseka okuchaphazelekayo kunye nokudakumba (20%)
- ukuphazamiseka kwengqondo (20%)
- ixhala (ukuya kuma-50%)
- uloyiko loluntu (32%)
- uphakuko (15%)
- ukuphazamiseka kwengqondo okunyanzelekileyo (20%)
- ukusetyenziswa kakubi kweziyobisi (20-30%)
Kungakhathaliseki ukuba kutheni ufunda le bhulogi, ndiyathemba ukuba ekugqibeleni, uya kuqonda kakuhle indlela yokutya kwe-ketogenic ingaba yonyango oluphambili okanye olongezelelweyo lwe-ADHD okanye iimpawu ze-ADD.
I-ADHD kunye ne-Hypometabolism
I-Hypometabolism ligama esilisebenzisayo ukuchaza iindawo zobuchopho ezingawasebenzisi kakuhle amandla (hypo=low; metabolism=ukusetyenziswa kwamandla). Abantu abane-ADHD banemimandla yobuchopho engasebenzi ngokwaneleyo kwaye ichongiwe njengengqondo ye-hypometabolism kwizakhiwo ezithile. I-Hypometabolism kwingqondo ye-ADHD ibonwa kwi-prefrontal cortex (ubukhulu becala ngasekunene), i-caudate nucleus, kunye ne-anterior cingulate. Singabona kwakhona umphumo owenziwe ngokubanzi kakhulu ekuthathweni kwe-glucose kwingqondo ye-ADHD yabo bantu badala baneempawu ze-hyperactivity.
I-Global cerebral glucose metabolism yaba yi-8.1% ephantsi kubantu abadala abanomdla kakhulu kunolawulo oluqhelekileyo.
Zametkin, AJ, Nordahl, TE, Gross, M., King, AC, Semple, WE, Rumsey, J., ... & Cohen, RM (1990). I-Cerebral glucose metabolism kubantu abadala abane-hyperactivity yokuqala komntwana. DOI: http://doi.org/10.15844/pedneurbriefs-4-11-4
Kwizifundo zezilwanyana, enye yeendlela ze-methylphenidate (ethengiswa njengeRitalin kunye namanye amagama eziyobisi) kukuba iyeza linyusa ukunyuswa kwe-glucose kwingqondo. Iingxaki nge-glucose hypometabolism kule mimandla yobuchopho ikhankanywe ngasentla ikhona ebantwaneni, abafikisayo kunye nabantu abadala. Abantu abadala abafunyaniswa bene-ADHD njengabantwana banemimandla yeglucose hypometabolism kwingqondo njengabantu abadala.
Kukho nobungqina bokuba ukuhluka kofuzo kuko okubangela ukuba i-glucose hypometabolism yenzeke, ngokukodwa ekusebenzeni kwee-receptors ezibalulekileyo ezifana ne-GLUT3. Xa i-GLUT3 isebenza ngokufanelekileyo, idibanisa i-glucose kwi-neurons kwaye ifumaneka ikakhulu kwii-axons kunye ne-dendrites. Kodwa kubantu abane-ADHD, sibona ukuba i-polymorphisms yemfuza inefuthe kubuchule be-GLUT3 bokusebenza ngokufanelekileyo kwaye oku kunokuba sisiphumo seengxaki zokuqala ze-neurocognitive ekucingelwa ukuba zibe negalelo kumngcipheko we-ADHD.
Ukutya kwe ketogenic kunceda njani ingqondo ye-hypometabolism kwi-ADHD
Hmmm. Ngaba bekungayi kuba kuhle ukuba bekukho enye ifuel ye-ADHD/ADD ingqondo? Omnye ongazange athembele kwi-glucose okanye kufuneka ajongane nabathuthi be-GLUT3 abangalunganga? Ngethamsanqa kukho! Kwenzeka ukuba kukutya kwe-ketogenic.
Izidlo ze-Ketogenic zibonelela ngenye ifuel yengqondo eyaziwa ngokuba yi-ketones. Ezi ketones ziya ngqo kwingqondo njengomthombo wamafutha. Akukho nto yothutho ye-GLUT efunekayo. I-Ketones zisebenzisa i-monocarboxylate transporters (MCTs), oyifumanayo eninzi kunye nokutya okunempilo okunamafutha kwi-ketogenic diet.
Kwaye into ephambeneyo kukuba, ii-ketones azincedi kuphela i-mitochondria yakho ekhoyo isebenze ngcono, kodwa zikhuthaza iiseli zakho zengqondo ukuba zenze okungakumbi. Kwaye kuninzi onokukwenza ngaloo nto inkulu yolawulo lwamandla obuchopho. Ngokukodwa ukuba kwenzeka kwilobe engaphambili.
Ngokungathi ukubonelela ngesinye isibaso sobuchopho kwingqondo ye-hypometabolic yayinganelanga, ii-ketones zikwanyusa amandla e-metabolism ngokunyusa i-neuronal cell mitochondria. IMitochondria ziibhetri zeeseli zakho. Mandiyicacise. Ezi mitochondria zincinci zinje ii-reactors zamandla. Igama elithi “iibhetri” alizenzi ngokusesikweni.
Kodwa linda. Kukho ngaphezulu.
Iiketones zivelisa amandla ANGAPHEZULU kuneglucose. Ukuchaneka, malunga ne-48 ATP vs. i-36 ATP oyifumana kwi-glucose.
Kukho iposti encinci yebhlog malunga ne-ketosis, mitochondria, kunye nobuchwephesha bendlela ii-ketones ezenza ngayo i-ATP. Apha (enkosi, Siimland).
Uphando lubhideke ngokupheleleyo kwaye alungqinelani ngokuthe ngqo ukuba ingakanani i-ATP efunwa yiseli, singasathethi ke ukuba leliphi inqanaba lamandla ekufuneka iseli liphuhle ngokuchaseneyo nokusebenza okuncinci. Kwaye uphando alucacanga kancinci malunga nokuba ingakanani na i-ATP ye-neuron eqhelekileyo, i-astrocyte, okanye iseli yeglial enokuthi isebenzise ngokufanelekileyo. Yazi nje ukuba ingqondo yakho isebenzisa i-70% yayo yonke i-ATP oyenzayo emzimbeni wakho wonke. Kwaye uya kuqala ukuqonda ukubaluleka kokufikelela kwii-ketones njengomthombo wamandla kwingqondo ye-ADHD.
“Kodwa yima kancinci!” usenokuba uthi kum njengoko ufunda le bhlog. Ingaba le nto inento yokwenza neempawu zam? I-ADHD/ADD ineenqobo zokuxilonga. Kwaye i-subset yaloo migaqo iwela phantsi koko kubizwa ngokuba kukungasebenzi kakuhle kwesigqeba.
Ukungasebenzi kakuhle kwe-Executive Dysfunction, ekwabizwa ngokuba yintsilelo yokusebenza okanye ukuphazamiseka, kuxa ingqondo inexesha elinzima kunye nezakhono zokuhoya, inkumbulo, ukucinga okuguquguqukayo, kunye nombutho / ulawulo lwexesha.
https://www.verywellmind.com/what-is-executive-dysfunction-in-adhd-5213034
Ukungasebenzi kakuhle kwe-Executive lobes kuvela kwilobes zangaphambili ezaphukileyo. Iilobe zangaphambili ezaphukileyo zinokuvela kumonzakalo wentloko, ukubetha, okanye ukungafumani mafutha aneleyo okubaleka.
Kwaye loo nto, umhlobo wam ofunda iblogi, yindlela ukutya kwe-ketogenic kunokunyanga ngayo i-hypometabolism yangaphambili ye-lobe eyinxalenye yenkqubo yesifo ephantsi kweempawu zakho ze-ADHD / ADD.
I-ADHD kunye ne-Neurotransmitter Ukungalingani
Kukho ukungalingani kwe-neurotransmitter kwi-ADHD kunye ne-ADD. Ezi ziquka i-serotonin, i-dopamine, i-noradrenaline, i-glutamate, kunye ne-GABA. Ukongezelela, kukho ukuthotywa okubonwa kwinto ebalulekileyo ebizwa ngokuba yi-brain-derived neurotrophic factor (BDNF). Ngelixa kungengobuchwephesha i-neurotransmitter, yenza impembelelo kwi-glutamate/GABA inkqubo kwaye ke iya kufakwa.
Serotonin
Umahluko kwimbonakalo yemfuza efunyenwe kwabo bane-ADHD iguqula ukusebenza kwe-serotonin receptors. Oku kuthetha ukuba indlela iseli yemithambo-luvo ifumana ngayo kwaye isebenzise i-serotonin ye-neurotransmitter iyatshintshwa. Umahluko kwezi zamkeli kunye nendlela ekuchaphazela ngayo uqhagamshelo phakathi kolwakhiwo lobuchopho kucingelwa ukuba zinefuthe kuphazamiseko lokufunda nokukhumbula esilubona kubantu abane-ADHD. Amanqanaba ancitshisiweyo e-serotonin kucingelwa ukuba anxulumene neempawu zokungxama ezibonwa kwezinye iimbonakaliso zokuphazamiseka.
Dopamine
Olunye ukungasebenzi kakuhle kwe-neurotransmitter okubonwa kwi-ADHD yi-dopamine. Iithiyori zakwangoko zacebisa ukuba amanqanaba aphantsi e-dopamine, kunye namanye ama-neurotransmitters, ayengoyena nobangela we-ADHD. Le ithiyori sele ihambile isiya kwingcinga yokuba ingxaki ayibangelwa kukuba akukho dopamine yaneleyo kodwa ngenxa yokuba kukho amanqanaba aphezulu abathuthi be-dopamine. Abathuthi beDopamine bavumela i-dopamine ukuba ingene kwiseli yemithambo-luvo ngokusebenzisa i-presynaptic membrane esebenza kakuhle.
Nikela ingqalelo koko ndikubhalileyo. Ukuze i-dopamine isetyenziswe, kufuneka ube ne-presynaptic membrane esebenza kakuhle. Oku kuya kuba yimfuneko kamva njengoko sixoxa ngonyango.
Ukuba nabathuthi be-dopamine abaninzi emsebenzini kuthetha ukuba i-dopamine ayixhonywanga ixesha elide ngokwaneleyo kumgca we-presynaptic ngexesha elifanelekileyo. Iyacocwa kuzo zonke ezo zamkeli. Ayinakuyenza into yayo!
Ngenxa yokuba i-dopamine ayikwazi ukwenza umsebenzi wayo, umntu one-ADHD ufumana kunzima ukufuna uyolo kwaye azive evuzwe ngezinto eziqhelekileyo eziyonwabisayo imini yonke. Baye badityaniswa ukuze bafune i-dopamine engakumbi. Yiyo loo nto abantu be-ADHD benokuphuhlisa iingxaki ngokusetyenziswa kwe-smartphone, imidlalo yekhompyuter, kunye nokutya okucutshungulweyo okugqithisileyo. Zonke izinto ziyilwe ngononophelo ukunika impendulo ephezulu ye-dopamine kwingqondo. Kukho imvakalelo eyahlukileyo yokungonwabi ngaphandle kwale misebenzi ivuselelayo kunye nokutya. Konke oku kukhokelela ekubeni uzive ungaphumli, uziphathe ngokungxama, kwaye ube neengxaki zokuhoya.
Phakathi kwezinto ze-neuro-chemicals, kukho i-dysregulation eyaziwayo ekuveliseni i-neurotransmitters; ngokuyintloko i-dopamine kunye ne-nor-adrenaline.
Fayed, NM, Morales, H., Torres, C., Coca, AF, & Ríos, LF Á. (2021). Ingqondo yeMagnetic Resonance Imaging kwi-Attention-Deficit/Hyperactivity Disorder (ADHD). https://link.springer.com/chapter/10.1007/978-3-030-61721-9_44
Iiyantlukwano ezininzi ezahlukeneyo zemfuza zinegalelo kwimiba yokusebenza kwe-dopamine ebonwa kwabo bane-ADHD kunye ne-ADD. Kucingelwa ukuba ukuguquguquka kwemizila yemfuza ngokwamanqanaba ahlukeneyo kufak’ isandla kuzo zonke iintetho ezininzi zesi sifo sizibona ebantwini. Umzekelo, iipolymorphisms ze-COMT ezichaphazela inkqubo ye-dopaminergic zinxulunyaniswa kakhulu neempawu ze-ADHD kunye nokonakala kwentlalo.
Norepinephrin
I-Norepinephrine yi-neuromodulator enendima ebalulekileyo, kunye ne-dopamine, ekuvumeleni i-cortex yangaphambili ukuba isebenze. Khumbula, sixoxe nge-prefrontal cortex kunye nento eyenzayo ngaphambili kule post yebhlog. I-prefrontal cortex engasebenziyo iya kukhokelela kukusilela ekusebenzeni okuqhelekileyo okuhlala kuludidi olusezantsi lweempawu ezibonwa kuxilongo lwe-ADHD/ADD.
Nangona uninzi lophando luthanda ukugxila kwi-dopamine, iimpembelelo ze-norepinephrine kwi-prefrontal cortex zinamandla kwaye zibaluleke kakhulu ekuqondeni iimpawu ze-ADHD. Xa i-norepinephrine isebenza kakuhle, inceda kwimemori yokusebenza kunye nengqalelo. Abantu abane-ADHD/ADD baxela imiba enzulu ngenkumbulo yokusebenza kunye nengqalelo.
Siyazi ukuba i-norepinephrine ibandakanyeka, ngokuyinxenye, kuba amayeza akhethiweyo e-noradrenergic (umzekelo, i-clonidine, i-guanfacine) anokunceda ukunyanga i-ADHD.
Kwaye kwakhona, sijongene nomba wabathuthi. Akunjalo ukuba kukho i-norepinephrine eninzi kakhulu okanye encinci, kodwa sibona ukuhluka kofuzo oluchaphazela indlela into esele ikhona ishukunyiswa kwaye isetyenziswe ngayo. Kwaye kwakhona, siyabona ukuba umahluko othile wemfuza obonwa kwi-ADHD kunye ne-ADD ibandakanyeka kwindlela umthuthi we-norepinephrine (NET) osebenza ngayo.
Glutamate kunye ne-GABA
Sixoxa ezi neurotransmitters zimbini kunye kuba ziyinxalenye yenkqubo entle esebenza kunye. Kwi-ADHD, sibona ukungalingani kule nkqubo ye-neurotransmitter. Amanqanaba e-Glutamate kwi-prefrontal cortex, umzekelo, aya kuba nefuthe ngokuthe ngqo kumanqanaba e-dopamine kunye ne-vice-a-versa.
Kwiingxaki ezithile ze-neurodevelopmental, ezifana ne-ADHD, sibona ukungalingani phakathi kwe-excitatory glutamate neurotransmitter kunye ne-inhibitory GABA. I-dopamine receptor (I-DRD4) ukungasebenzi kakuhle okubonwa kwi-ADHD kudala indawo apho kukho i-glutamate eninzi engqondweni. Kwaye asifuni itoni ye-glutamate ijinga nje engqondweni, ingalungelelaniswa yi-GABA. Ngenxa yokuba ixesha elide, oku kubangela umonakalo kwiiseli zengqondo kunye nezakhiwo zengqondo.
I-Glutamate yinto ebalulekileyo yophawu lwengqondo ye-neurotoxic. Ukugqithisa kwe-glutamate kunokuvelisa ukufa kwe-neuronal ngokusebenzisa iinkqubo ze-excitotoxic. Kucingelwa ukuba i-glutamate kwiisekethe ezingaphambili isisilawuli esibalulekileyo se-dopamine, kwaye ngendlela yengxelo ukuxinana kwe-dopamine kunokuchaphazela ukuxinana kwe-glutamate.
Fayed, NM, Morales, H., Torres, C., Coca, AF, & Ríos, LF Á. (2021). Ingqondo yeMagnetic Resonance Imaging kwi-Attention-Deficit/Hyperactivity Disorder (ADHD). Kwi Uhlaziyo lwePsychiatry kunye Neuroscience (iphe. 623-633). Springer, Cham
Abantwana abane-ADHD babonisa ulawulo oluhlwempuzekileyo lokuthintela kunye nokunciphisa kakhulu i-GABA kwi-striatum, eyisisakhiwo sobuchopho esibandakanyekayo ekumiseni ukuba zeziphi izenzo ekufuneka zenziwe kunye nokufunda malunga nokuba zeziphi na ezo zenzo ezifanele ukuphinda. Amanqanaba asezantsi okanye ukusetyenziswa kwe-GABA kucingelwa ukuba negalelo kwiimpawu zokuthintela ukuziphatha okubonwa kwi-ADHD.
Igalelo lolu hlobo oluthile lokungalingani kwe-neurotransmitter alingabalulekanga. Kwaye iziphumo zezi zimbini ze-neurotransmitters zingekho kwi-balance kucingelwa ukuba zibe negalelo ngqo kwi-etiology ye-ADHD kunye nemiphumo ye-neurobiological eqhubekayo ibe ngumntu omdala.
I-brain-derived neurotrophic factor (BDNF)
I-BDNF ifunyenwe ithotywe phantsi kwi-ADHD. Okunye koku kusenokuba ngenxa yokwahluka kofuzo olufunyenwe kolu luntu. Kwaye abantu abane-ADHD/ADD baziva le nto ingonelanga. Ngenxa yokuba i-hippocampus yakho, isakhiwo sobuchopho esinceda ukucubungula iinkumbulo zexesha elifutshane, sisebenza kakhulu, kwaye sidinga i-BDNF eninzi ukuze isebenze ngokufanelekileyo. Kwaye oku kuthotywa kwesi sixhobo kusenokuba kutheni sibona imiba enenkumbulo yexesha elifutshane kunye nokusebenza kubantu abane-ADHD. Ukwafuna i-BDNF eyaneleyo ukuze ufunde nje ngokubanzi. Uyidinga ukuze usayine kwi-glutamatergic kunye ne-GABAergic (ergic=making) synapses, kwaye idlala indima ekuhanjisweni kwe-serotonin kunye ne-dopamine phakathi kweeseli. Eyona nto iphambili kukuba abantu abane-ADHD abanalo ngokwaneleyo le nto ilungileyo. Kwaye kufuneka sifumane indlela yokuyandisa.
Ukutya kwe-ketogenic kunceda njani ukungalingani kwe-neurotransmitter okubonwa kwi-ADHD
Ke ukutya kwe ketogenic kunokuphucula njani iimpawu ze-ADHD? Emva kwayo yonke loo nto, kubonakala ngathi i-ADHD ininzi yemfuza. Ukutya okune-ketogenic kunokuguqula njani ukubonakaliswa kofuzo olumisela ukuba i-neurotransmitters yethu isebenza njani (okanye ayi)? Ngaba unyango lokutya lunokuyitshintsha njani into enkulu ngolo hlobo?
Dopamine, Noradrenaline, kunye neSerotonin
Ngendikhe ndayikhankanya le nto ngaphambili, kodwa kukho iintlobo ezintathu zeetoni. Enye yezo ntlobo ibizwa ngokuba yi-beta-hydroxybutyrate (βHB). I-βHB ivelisa ngaphezulu kwe-enzyme ephakathi kwi-metabolism (imveliso yamandla) ebizwa ngokuba yi-nicotinamide adenine dinucleotide (NADH). Ikwenza oku ngendlela enzima onokuthi uyijonge Apha (jonga umfanekiso 3) ukuba unomdla kwelo nqanaba.
Ngeenjongo zethu apha, kubalulekile ukwazi ukuba oku kwandisa i-synthesis kunye / okanye umsebenzi we-neurotransmitters dopamine, i-noradrenaline, i-serotonin, kunye ne-melatonin.
Kwaye ukuba uyakhumbula ukufunda kwakho apha ngasentla, ukuhluka kofuzo kwi-neurotransmitter receptors kunye ne-transporter expression ye-serotonin, i-dopamine, kunye ne-norepinephrine yimiba ebonwa ngobuchopho be-ADHD. Ukwenza ngakumbi kwinto nganye kunokuba luncedo kakhulu.
- Ukonyuka kwe-serotonin kunokuphucula ukungxamiseka, ukufunda kunye nokuphazamiseka kwememori
- Ukonyuka kwe-dopamine kunokunciphisa ukungazinzi kunye nokuphucula ingqalelo
- Ukonyuka kwe-norepinephrine kunokuphucula imemori yokusebenza kunye nokuqwalaselwa
Kuya kubakho ukulunga ngakumbi kwe-neurotransmitter okujikelezayo, kwaye kuya kuthetha ukuba kuya kubakho ngaphezulu kokuhlala kukho kwii-synapses apho banokusebenza khona umlingo wabo. Kwaye oku kulawulwa kwee-neurotransmitters eziphambili zenziwa ngendlela elungeleleneyo kunye nokutya kwe-ketogenic.
Ngokungafaniyo namayeza apho ii-neurotransmitters ezithile zonyuswa okanye zenziwe ukuba zihlale ixesha elide kangangoko kunokwenzeka kwi-synapses, akuyi kuba nemiphumo emibi yeyeza. Sonke siyazi kakuhle, umzekelo, imiphumo emibi abantu abahlangabezana nayo xa bethatha i-SSRIs ukwandisa ixesha le-serotonin ehlala kwii-synapses eziza kusetyenziswa. Siyazi ukuba i-gabapentin, eyenzelwe ukunyusa amanqanaba e-GABA engqondweni inokudala iziphumo ezinobungozi bokulala, umzekelo. Olu hlobo lwento alukwenzeka nje kwi-ketogenic diet.
Kodwa kuthekani nge-glutamate kunye ne-GABA?
Njengoko kuxoxiwe ngasentla, ingqondo ye-ADHD iyasokola kunye ne-glutamate eninzi kunye ne-GABA encinci kakhulu. Ukutya kwe-Ketogenic kunokunyusa ukusebenza kwe-glutamic acid decarboxylase, ekhuthaza ukuhlanganiswa kwe-GABA kunye nokuguqula umsebenzi we-enzyme ogcina i-GABA ixesha elide kwii-synapses. Ke kwingqondo ye-ADHD, oku kuthetha ukufikelela ngakumbi kwi-neurotransmitter yokuthintela efunekayo ukunceda ukulungelelanisa amanqanaba aphezulu e-glutamate.
Kwizifundo zezilwanyana, enye yeefom zemizimba ye-ketone eyaziwa ngokuba yi-acetoacetate yafunyanwa ukunciphisa ukuhanjiswa kwe-neurotransmission kwi-hippocampal synapses, enokuphucula okanye ubuncinane ukukhusela umsebenzi wememori. Abantu abane-ADHD kunye ne-ADD bahlala bekhalaza ngeengxaki zokukhumbula ixesha elifutshane kunye nokufunda. Ukulungelelanisa umsebenzi we-neurotransmitter kwizinto ezibalulekileyo zememori ezifana ne-hippocampus zinokubonisa ukuba luncedo ekunciphiseni iimpawu.
Ukusebenza kweMembrane kunye ne-neurotransmitter balance
Awukwazi nje ukuba nencoko malunga nebhalansi ye-neurotransmitter ngaphandle kokuxoxa ngomsebenzi we-neuronal membrane. I-βHB inceda i-neuronal membranes ukuba iphinde ibuyele, kwaye ukubanako okuphuculweyo kokuphinda kuphinde kubekho kunenzuzo eninzi kwingqondo ye-ADHD/ADD.
I-repolarization ye-neuronal membranes, ephuculwe yi-βHB ivumela iseli ukuba iqokelele izondlo (ezihlala zisilela kwi-ADHD / ingqondo ye-ADD) ukwenza i-neurotransmitters kwindawo yokuqala. Khumbula xa sixoxe ngemiba kunye ne-neurotransmitter receptors kunye nabathuthi kwi-ADHD / ADD ingqondo?
Ewe, ukwakhiwa kwee-enzymes ezimisela ukuba ingakanani i-neurotransmitter efumana ukuxhoma kwi-synaptic cleft, kwaye ixesha elingakanani into egqitywe yi-membrane repolarization. Ukukwazi kwe-synaptic clefts ukuhlala uvakalelo kwii-neurotransmitters ezivelayo (ezifana ne-dopamine, i-serotonin, kunye ne-norepinephrine) kukwaxhomekeke ekusebenzeni kwakhona kokusebenza okunempilo.
I-brain-derived neurotrophic factor (BDNF)
Izidlo ze-Ketogenic ziyaziwa ngokulawula ukuveliswa kwe-BDNF. Kucingelwa ukuba le nto ingaba yindlela ebalulekileyo evumela ukuba baphucule izifo ezahlukeneyo ze-neurological, ezifana nokulimala kwengqondo ebuhlungu (TBIs) kunye ne-dementia. I-Ketones ilawula i-BDNF kwindima yabo njenge-molecule yokubonisa, ukuguqula izakhi zofuzo kunye nokucima ngendlela enokuthi yenziwe ngakumbi le nto. Ke ukuvelisa ii-ketones, kwi-ketogenic diet, kuya kudala i-BDNF eninzi kwi-ADHD/ADD ingqondo.
Imizila yemfuza ayidalelwa
I-ADHD ithathwa njengephenjelelwa kakhulu yimizila yemfuza. Kwaye ngalo naliphi na ixesha isifo sixoxwa ngalo ndlela, abantu banokufumana umbono ongalunganga malunga nokuba bayakwazi "ukulungisa" okanye ukulungelelanisa ii-pathologies ezisisiseko ezinxulumene nemeko.
Asazi ukuba zininzi kangakanani iingxaki ngezi zinto kwi-ADHD zivela kukungasebenzi kakuhle kwe-neuronal membrane ngenxa yezinto ze-epigenetic (umzekelo, i-hypometabolism ngenxa yokutya, ukunqongophala kwe-micronutrient, neuroinflammation engapheliyo, uxinzelelo lwe-oxidative).
Nangona iingxaki ze-receptors kunye nabathuthi kuthiwa zenzeke kwinqanaba lezofuzo kulabo abanengqondo ye-ADHD, ndifuna ukuya kwirekhodi njengokunxibelelana ukuba ndicinga ukuba kunokwenzeka ukuba ukutshintsha indawo apho ezo mfuzo zibonakaliswe kunokuthetha ukuphuculwa kweempawu. . Indlela imbonakalo yemfuza eyenzeka ngayo kwi-serotonin, i-dopamine, kunye nabathuthi be-norepinephrine kunye ne-receptors inokulungeleka kwiimpembelelo ze-epigenetic.
Kwaye ungenelelo lwe-epigenetic, njengokutya kwe-ketogenic, lunamandla kakhulu ekuphembeleleni ukubonakaliswa kofuzo. I-Ketones ibonakalisa iimolekyuli, oku kuthetha ukuba banamandla okuguqula nokucima imfuza. Ngenxa yokuba uxelelwe ukuba kukho into ezuzwayo ayithethi ukuba awunawo amandla okwenza utshintsho ukulungisa indlela eyenzeka ngayo loo ntetho.
I-ADHD kunye ne-Neuroinflammation
Abantu abane-ADHD banamanqanaba abalulekileyo e-neuroinflammation eza kubo ukusuka kumacala amaninzi ahlukeneyo. Ukudumba kunokubangelwa ngenxa yezizathu ezininzi. Ukutya okuphezulu kwi-fructose (ezo ziselo ziswiti kwivenkile ethengisa lula) kunokunyusa ukudumba. Ungcoliseko lunokwandisa ukudumba. Umqobo ovuzayo wegazi-ingqondo ovumela i-toxins ukuba ingene ebuchotsheni inokubangela ukudumba. Izixinzelelo ezibukhali, njengokuthatha uviwo okanye ukuvuthela itayara kuhola wendlela, kunokonyusa ukudumba. Kwaye ukungasebenzi kakuhle kwamajoni omzimba kunokunyusa ukuvuvukala. Nika ingqalelo kwesokugqibela kuba ukudumba okubangelwa kukungasebenzi kakuhle kwamajoni omzimba kubonakala kubaluleke kakhulu kwi-ADHD.
Ngoko ke ithetha ukuthini loo nto? Xa amajoni ethu omzimba esebenza, into ebizwa ngokuba ziicytokines iye iveliswe. Ezi ziimolekyuli ezincinci ezibonisa amajoni omzimba ukuba enze ntoni ukugcina “umntu ombi” abasandula ukuxelelwa ukuba ukho emgceni. Kodwa iicytokines azikhohlakali xa zisilwa nabangeneleli abahlukeneyo. Benza umonakalo omkhulu. Khawube nomfanekiso-ngqondweni wesiphithiphithi esileqa amapolisa kunye nawo wonke umonakalo owenzekayo njengoko elandela umntu ombi ngokuqina okukhulu kunye nesantya esiphezulu.
Yileyo ndlela i-cytokines eqengqa ngayo. Basenokuthi okanye bangambambi umntu ombi, kwaye kukho inkunkuma enkulu yokucoca. Kwaye kuthatha umsebenzi omninzi, izixhobo, kunye nezibonelelo ukwenza oko kucoca. Kwingqondo, oko kuthetha iitoni zamandla asetyenzisiweyo (abasebenzi), ezinye iiseli ezisempilweni kwaye zinokuthatha ukudelela (izixhobo), kunye ne-micronutrients eninzi (izixhobo) kunokuba uzifumana ekutyeni kwakho.
Ngoku khawufane ucinge ukuba zininzi iimoto ezileqayo ngalo lonke ixesha, njengokungaphumli (engapheliyo). Ekugqibeleni, ukucoca kunye nokulungiswa kuya kuba ngasemva. Isixeko kunye nendlela yayiza kuqalisa ukubonakala njengenkunkuma eshushu. Leyo yingqondo yakho ejongene ne-neuroinflammation engapheliyo.
Nali inqaku elikhulu elandisa lo mzekeliso ngendlela ekunceda ukuba uqonde i-neuroinflammation kunye noxinzelelo lwe-oxidative, kunye nendlela ezinxibelelana ngayo enye kwenye!
Eyona ndlela ndingabonisa ngayo ukuba ukudumba kubaluleke kangakanani kwi-ADHD kukubonelela ngesicatshulwa kwinqaku lophando endilitsalileyo ukuba ndibhale esi sithuba.
Ngelixa busanqongophele, obu bungqina bubandakanya i-1) i-comorbidity engentla ye-ADHD kunye nokuvuvukala kunye nokuphazamiseka kwe-autoimmune, i-2) izifundo zokuqala ezibonisa ukunxulumana ne-ADHD kunye nokwanda kwe-serum cytokines, i-3) ubungqina bokuqala obuvela kwizifundo zemfuzo ezibonisa ubudlelwane phakathi kweepolymorphisms kwimizila ehambelana nayo. ngeendlela zokuvuvukala kunye ne-ADHD, i-4) ubungqina obuvelayo bokuba ukuvezwa kobomi baselula kwizinto ezininzi zomngcipheko wokusingqongileyo kunokonyusa umngcipheko we-ADHD ngokusebenzisa indlela yokuvuvukala, kunye ne-5) ubungqina obuchwephesha obuvela kwiimodeli zezilwanyana zokuvuselela umzimba womama obhala iziphumo zokuziphatha kunye ne-neural ezihambelanayo. I-ADHD.
UDunn, GA, Nigg, JT, & Sullivan, EL (2019). I-Neuroinflammation njengomngcipheko wokunqongophala kwengxaki yokungasebenzi kakuhle. https://doi.org/10.1016/j.pbb.2019.05.005
Ngoko ke makhe sihlolisise ukubaluleka koku sisandul’ ukukufunda. Abantu abane-ADHD kunokwenzeka ukuba babe nokuvuvukala kunye ne-autoimmune disorder comorbidities. Ngamanye amazwi, kukho into engalunganga kwi-immune system, kwaye ibangela ukuvuvukala ngenxa yoko. Ngoko akumangalisi, xa bevavanya abantu abane-ADHD kwiimpawu zegazi zokudumba, bafumanisa ukuba banama-cytokines amaninzi adumbileyo kunolawulo.
Xa sijonga izinto zophuhliso lwe-ADHD, sibona ukuvezwa kobomi bokuqala kwimingcipheko yokusingqongileyo ebangela ukuvuvukala. Kwiimodeli zezilwanyana, baye bachonga iindlela phakathi kokusebenza kwamajoni omzimba ngexesha lokukhulelwa kunye nobuchopho obulandelayo kunye nokutshintsha kokuziphatha kwinzala efana naleyo ibonwa kubantu abane-ADHD.
Ukuba konke oko akwanelanga ukukuqinisekisa ukuba i-neuroinflammation ibaluleke kakhulu kwi-ADHD, ndivumele ndikuxelele malunga ne-polymorphisms yemfuza abayifumene ehambelana neendlela ezenza ukudumba.
Nokuba yonke le mibutho ifunyaniswa iyimbangela okanye hayi, ndingaphikisa, ayinamsebenzi. Asiyithobeli ngokugqibeleleyo indlela eyimbangela yezinto ezininzi, kwaye siqhwaba amayeza phezulu ukulungisa le nto sicinga ukuba iyaqhubeka, kwaye siyenza ngalo lonke ixesha. Ke kutheni singakhange sithathele ingqalelo ukuvuvukala njengento ekujoliswe kuyo ekuncedeni ukunciphisa iimpawu ze-ADHD?
Ngethamsanqa, uninzi lwabaphandi abakrelekrele ngokwenene sele bevumelana nam. Andifuni ucinge ukuba yinto nje endiyizele ndedwa le.
Ngokusekwe kwi-hypothesis yethu, ukujolisa kwi-neuroinflammation kunokusebenza njengongenelelo olutsha lonyango lokunyanga i-ADHD.
Kerekes, N., Sanchéz-Pérez, AM, & Landry, M. (2021). I-Neuroinflammation njengekhonkco elinokwenzeka phakathi kwengqwalasela-intsilelo / i-hyperactivity disorder (ADHD) kunye neentlungu. https://doi.org/10.1016/j.mehy.2021.110717
Le neuroinflammation ibalulekile nakwinto esiyifundayo kwicandelo lokugqibela malunga nokungalingani kwe-neurotransmitter. Ukuvuvukala kudala i-neurotransmitters enomdla ngakumbi kwaye ikhuthaza ukuphazamiseka esikubonayo phakathi kwe-glutamate kunye ne-GABA. Ukuvuvukala kudala indawo ebuchosheni apho kungenakukwazi ukwenza imilinganiselo efanelekileyo ye-GABA kwi-glutamate. Mhlawumbi kungenxa yokuba iphantsi konyanzeliso (kuzo zonke ezo zinto zileqayo).
Akukho ngqiqweni ukucinga ukuba ubuya kwenza ii-neurotransmitters zikuxelela ukuba ugodole kwaye yonke into ilungile xa une-neuroinflammation engapheliyo. Kungenxa yoko le nto kubalulekile ukunikela ingqalelo kwiimpawu zakho. Yindlela yengqondo yakho yokukuxelela ukuba kukho into engalunganga kakhulu. Ifuna ukuba ungahoyi ukuleqa kweemoto ezingapheliyo kwaye zenza umonakalo. Ifuna ukuba unikele ingqalelo. Mhlawumbi ayingomntu othanda ukuzama ukufumana imimiselo ekunceda wenze ngathi umonakalo awenzi.
Masenze ukudumba ibe yenye yeethagethi ezingundoqo zongenelelo esizibona zinegalelo kwiimpawu kwi-ADHD/ADD ingqondo.
Izidlo ze-ketogenic zilunyango lwe-neuroinflammation olubonwa kwi-ADHD
Njengoko sixoxile ngasentla, i-neuroinflammation ebonwe kwi-ADHD iza ngokuyinxalenye kwiimpendulo ezingasebenziyo zokuzikhusela komzimba. Andiqhelekanga ukuxoxa ngemiphumo yokutya kwe-ketogenic kwi-immune system, kodwa ibonakala ibaluleke kakhulu kwi-etiology kunye nokuboniswa kweempawu kunye nale ndawo.
Nangona kunjalo, andifundanga kakuhle kwi-immune system, ngoko ke ndiza kuba ngokubanzi apha kwaye ndenze uphando olongezelelweyo ukuba uziva ufuna.
Izidlo ze-Ketogenic ziphakamisa kwaye zilinganise umsebenzi wokuzivikela omzimba. Sizisebenzisa ukunceda ukunyanga ezinye iintlobo zomhlaza, ngokuyinxenye, ngenxa yempendulo yokhuselo lomzimba kwi-T-cell activation. Abaphandi bafumene iziphumo ezilungileyo ezaneleyo zokutya kwe-ketogenic ekusebenzeni kwamajoni omzimba ukuba i-RCT yaqaliswa ukubona ukuba ingasetyenziselwa ukubonelela ngento ekhuselayo kwi-COVID.
Abanye abantu bacinga ukuba oku kunyuswa kwamajoni omzimba kwenzeka ngenxa yotshintsho lokutya kwe-ketogenic kwi-gut microbiome. Enye yeefutha ezizithandayo ze-guts yi-butyrate, icandelo lemizimba ethile ye-ketone kwaye inokufumaneka kwixabiso eliphezulu kwibhotela. Ndihlala ndiyifumana le nto imangalisa kakhulu, xa kugxilwe ngoku kubonakala ngathi kukho konke malunga ne-prebiotic fiber njenge-superhero yempilo yamathumbu kunye nokuphila kakuhle. Kwakhona kufuneka ndibonise ukuba ukuphilisa okunye kwenzeka kwisithintelo segazi-ingqondo xa uhamba kwi-ketogenic diet.
Ke, imiphumo enenzuzo yokutya kwe-ketogenic inokuxhomekeka ekunyukeni kwengqondo kwi-KBs ukuhambelana nemfuno ye-metabolic kunye nokulungiswa kwe-BBB ephazamisekileyo. Njengoko iimpembelelo ze-KBs kwi-BBB kunye neendlela zabo zokuthutha kuyo yonke i-BBB ziqondwa ngcono, kuya kwenzeka ukuba kuphuhliswe ezinye iindlela zokuphucula izibonelelo zonyango ze-KBs zokuphazamiseka kwengqondo apho i-BBB iphazamiseka.
(KBs=imizimba yeketone; BBB=isithintelo sobuchopho)
Banjara, M., & Janigro, D. (2016). Iziphumo zokutya kwe-ketogenic kumqobo wegazi-ubuchopho.
I-DOI: 10.1093/med/9780190497996.001.0001
Isithintelo esisempilweni segazi-buchopho sithetha izinto ezimbalwa ezidadayo ziye phezulu kwingqondo yakho ezingezizo ezakhe. Kwaye xa unetyhefu okanye izinto ezidlula kweso sithintelo segazi-ingqondo engeyiyo, oko kukhokelela ekuqaliseni iicytokines kwaye kube negalelo kwi-neuroinflammation.
Ngoko qwalasela imiphumo yokutya kwe-ketogenic ekusebenzeni komzimba njengebhonasi edlala indima ebalulekileyo ekuncedeni ukunciphisa iimpawu zakho ze-ADHD / ADD ukunceda ukunciphisa iimpawu zakho.
Enye indlela yokutya kwe-ketogenic yokunciphisa ukuvuvukala ngokuthintela iindlela ezivuthayo. I-Ketones, ezenziwe ngobuninzi kwi-ketogenic diet, izibonakaliso ze-molecule, kwaye ukuba yi-molecule yomqondiso kuthetha ukuba zikhonza njengomthunywa, zixelela ezinye iijini ukuba zicime kunye nezinye izakhi zofuzo ukuba zivule. Kwaye izidlo ze-ketogenic zinciphisa ukuvuvukala ngale ndlela epholileyo kakhulu. Njengo, ngokuthe ngqo.
Kwicandelo elilandelayo, siza kufunda malunga nendlela ukuvuvukala okudlala ngayo indima kuxinzelelo lwe-oxidative kunye nokuba ukunciphisa le ndlela ye-pathological kunokuchaphazela njani iimpawu esizibonayo kwi-ADHD.
I-ADHD kunye noxinzelelo lwe-Oxidative
Uxinzelelo lwe-oxidative lwenzeka xa kukho ukungalingani kwamandla omzimba okujongana neeproducts ezenzeka nje ngokuphila. Izinto ezininzi zinokubangela uxinzelelo lwe-oxidative. Ukuphefumla nje kudala into ebizwa ngokuba ziintlobo zeoksijini esebenzayo (ROS). Ngoko umzimba wakho ulindele umlinganiselo othile we-ROS, ekubeni nje uphila. Kwaye akuyongxaki xa umonakalo/inkqubo ye-antioxidant ikwi-balance. Njengoko siza kuthetha kamva kule post yebhlog, senziwe ukuba sijongane neROS, ubuncinci ukuya kuthi ga kwinqanaba elithile. Kodwa amanqanaba esivezwe kuwo namhlanje awazange abekho kwimbali yakho yendaleko.
Siye sathetha nje ukudumba. Ngaba ukuvuvukala kwenza uxinzelelo lwe-oxidative ngakumbi? Ewe. Ewe, ngokuqinisekileyo iyakwenza oko.
Inkqubo yokuvuvukala ibangela uxinzelelo lwe-oxidative kwaye inciphisa umthamo we-antioxidant weselula.
Khansari, N., Shakiba, Y., & Mahmoudi, M. (2009). Ukuvuvukala okungapheliyo kunye noxinzelelo lwe-oxidative njengonobangela omkhulu wezifo ezinxulumene neminyaka kunye nomhlaza. https://doi.org/10.2174/187221309787158371
Ezi zi-ROS kufuneka zikhutshwe okanye zingathathi hlangothi. Kwaye ukuze umzimba wakho wenze oko, udinga i-micronutrients eninzi (i-cofactors) kunye nenqanaba elihle le-endogenous (eyenziwe ngaphakathi emzimbeni wakho) i-antioxidants. Abantu bakwasebenzisa i-antioxidants (umzekelo, i-turmeric, i-quercetin, i-vitamin C kunye ne-E), ukuzama ukunciphisa uxinzelelo lwe-oxidative.
Uxinzelelo lwe-oxidative alukho umdlalo. Uvunyelwe ukuba usebenze ungajongwanga ekuhambeni kwexesha, ufumana umonakalo kwiDNA yakho. Makhe sibuyele kwisifaniso sethu sokuleqa imoto. Iba ngathi ukuleqwa kweemoto kuphume esandleni kangangokuba izakhiwo ziyawa neendlela ziyawohloka. Kodwa ngoku, ulwazi lokulungiswa kwazo zonke ezi zinto lulahlekile kuzo zonke izidubedube. Kwaye ngoku abantu abazama ukwakha isixeko kwakhona, emva kwayo yonke loo nto yokuleqa iimoto, abanakuyenza kakuhle okanye ngendlela ezinzileyo. Lo ngumzekeliso womonakalo weDNA owenzeka ngoxinzelelo lweoxidative olungaqwalaselwanga. Njengoko unokucinga, izifo ezingapheliyo ziya kukhula ngenxa yoku.
Kukho iindlela ezininzi ezahlukeneyo apho i-ROS eninzi idalwe kunokuba yintoni umzimba wethu onokuyenza. Ngaphandle nje kokuphefumla kunye namandla okwenza i-metabolizing, ezinye zezinto ezinokonyusa umthwalo woxinzelelo lwe-oxidative okusingqongileyo kubandakanya:
- UV kunye ne-ionizing radiations
- ngco liseko
- izinyithi ezinzima
- Izityalo
- iziyobisi
- inambuzane
- cosmetics
- neencasa
- iziqholo
- izongezo zokutya
- iikhemikhali zeshishini
- Izinto ezingcolisa indalo
Zonke ezi zinto zonyusa kakhulu i-ROS kwaye zibangela oku kungalingani esikubhekisa kuko njengoxinzelelo lwe-oxidative. Uxinzelelo lwe-oxidative lukhokelela kumonakalo weseli kunye nezicubu, kwaye ubuchopho, ngokubanzi, bunovelwano ngakumbi kuyo.
Kodwa ingqondo ye-ADHD/ADD ingaphezulu. Hayi, ngokwenene, kwaye kuncwadi yophando. Kodwa ngaphambi kokuba sixoxe ngaloo nto, makhe sithethe ngamayeza asetyenziselwa ukunyanga i-ADHD.
Ngaphezulu kwayo yonke loo mithombo yokusingqongileyo yoxinzelelo lwe-oxidative echazwe ngasentla, amayeza abantu okunyanga iimpawu ze-ADHD angayenza mandundu ingxaki. Ukusetyenziswa kwamayeza e-ADHD afana neMethylphenidate (MPH), ethengiswa njengeRitalin kunye namanye amagama, kwandisa amanqanaba oxinzelelo lwe-oxidative.
Kwi-MPH kukho ubungqina bokwanda kwe-OS, ukhuselo lwe-AO olutshintshileyo kunye nokuvuvukala kwe-neuro kubantwana be-ADHD
I-Kovacic, i-P., kunye ne-Weston, i-W. I-Attention-deficit / hyperactivity disorder-unifying mechanism ebandakanya unyango lwe-antioxidant: I-Phenolics, iintlobo ze-oksijini ezisebenzayo, kunye noxinzelelo lwe-oxidative. https://www.biochemjournal.com/articles/23/1-2-10-853.pdf
Kuncwadi lophando, sibona amanqanaba aphezulu oxinzelelo lwe-oxidative kwingqondo ye-ADHD, kwaye oku kunokuvela kumngcipheko othile wemfuza kwi-ROS.
Omnye umzekelo woku zii-Organophosphates, ezifana ne-dimethyl phosphate (DMP; isibulali-zinambuzane). Uphononongo lwemfuzo lubonise ukuba ukuvezwa kumanqanaba aphezulu ale nto kwindawo idale umngcipheko ophezulu kakhulu wokuphuhlisa utshintsho oluchanekileyo esilubonayo kwi-ADHD kunye ne-dopamine receptors.
Iipesenti ezingama-59 zeemeko ze-ADHD kubantwana abavezwe yi-DMP abane- I-DRD4 I-genotype ye-GG yaba ngenxa yentsebenziswano yemfuza yendalo esingqongileyo. Emva kohlengahlengiso kwezinye i-covariates, abantwana abaphethe i I-DRD4 I-GG genotype, yayivezwe kumanqanaba aphezulu e-DMP (ngaphezu kwe-median), kwaye yayinomngcipheko owongezelelekileyo wokuphuhlisa i-ADHD.
Chang, CH, et al., (2018). Ukusebenzisana phakathi kokuvezwa kwe-organophosphate pesticide, uxinzelelo lwe-oxidative, kunye ne-polymorphisms yemfuza ye-dopamine receptor D4 yonyusa umngcipheko wokunqongophala / ukuphazamiseka kwengqondo ebantwaneni. https://doi.org/10.1016/j.envres.2017.10.011
Ke uxinzelelo lwe-oxidative lunokuba yinxalenye ye-etiology (iqala njani) ye-ADHD. Kodwa ngaba inendima ekugcinweni kwayo? Ndingathi ewe. Kukho iipolymorphisms kwiijini ezinxulumene nokudumba ezibonwa kwabo bane-ADHD. Ukunciphisa amanqanaba e-antioxidant abonwa kubantwana, abaselula, kunye nabantu abadala xa kuthelekiswa namaqela okulawula.
Uxinzelelo lwe-oxidative ngumba onjalo kwingqondo ye-ADHD/ADD kangangokuba enye ethandwa kakhulu kwaye kuxelwe ukuba unyango olumnandi kukusetyenziswa kwee-OPCs. Ii-OPCs zinamandla kakhulu e-antioxidants. Ndaqala ndafunda ngabo kwi-webinar yasimahla kwi-Psychiatry Redefined, onokuyibukela Apha. Andifuni ukuphuma kumxholo, ke andizukungena kwii-OPCs kule post yebhlog. Unokufunda ngakumbi malunga nabo apha:
Kodwa bendifuna ukubonisa ukuba uxinzelelo lwe-oxidative lujolise kunyango kwi-psychiatry esebenzayo. Awunakuba nenzuzo yomyalelo oqeqeshwe kumayeza asebenzayo. Ke ndishiya olu lwazi apha ukuba ufuna ukuphonononga ngakumbi uhambo lwakho lwempilo.
Kodwa njengoko siza kufunda, kukho iindlela ezininzi zokutya kwe-ketogenic kunceda ukunyanga uxinzelelo lwe-oxidative, ngaloo ndlela (kwaye mhlawumbi) uphucula iimpawu zakho. Enye indlela i-keto enokunceda ngayo i-ADHD.
Ukutya kwe-ketogenic kunciphisa njani amanqanaba oxinzelelo lwe-oxidative kubantu abane-ADHD
Zininzi iindlela eziphenjelelwa kukutya kwe ketogenic. Omnye umzekelo kukuba kukho ukwanda agmatine, i-neurotransmitter engaziwayo kakhulu eyenziwe kwi-amino acid L-arginine. Oku kwanda kwe-agmatine kwingqondo eyenzeka kwi-ketogenic yokutya ineepropathi ezibhalwe kakuhle ze-neuroprotective ezinceda ukukhusela ingqondo ye-ADHD kumanqanaba okwanda koxinzelelo lwe-oxidative.
Enye into yokwazi malunga nokutya kwe-ketogenic, malunga nemiphumo yabo kuxinzelelo lwe-oxidative, kukuba ii-ketones zingumthombo wamandla ococekileyo kakhulu. I-ROS engaphantsi idale i-ketones evuthayo ye-fuel kuneminye imithombo yamandla ephambili. Ngenxa yoko, i-βHB (uhlobo lomzimba we-ketone) iyanciphisa imveliso ye-ROS kwaye yandisa i-antioxidant yokukhusela.
Enye indlela yokutya kwe-ketogenic kunceda ngokuthe ngqo ukunyangwa kwe-oxidative kukuba i-βHB inciphisa umonakalo we-oxidative ngenxa yezithuko ze-excitotoxic (umzekelo, khumbula i-glutamate?) kwindawo apho kwenzeka khona umonakalo. Ngandlela ithile i-βHB inceda ukuthoba okanye ukulungisa umonakalo owenziwe luxinzelelo lwe-oxidative. Kwaye abaphandi bacinga ukuba oku kungenxa yokuphuculwa komsebenzi we-mitochondrial okanye ukuphembelela ukubonakaliswa kofuzo.
Kodwa linda, kukho nangakumbi okwenziwa kukutya kwe-ketogenic ukunceda ukunciphisa uxinzelelo lwe-oxidative.
Ukutya kwe-Ketogenic kusinceda senze ngakumbi i-antioxidant ebalulekileyo esiyenzayo emizimbeni yethu. Khumbula, sithethe malunga nendlela umzimba wakho wazi ngayo ukuba iROS iya kuba yinto. Kuba uphefumla kwaye utya kwaye ushukume kunye nezinto. Ngoko ngokucacileyo, inendlela yokujongana naloo nto. Kwaye ijongene nelo nqanaba liqhelekileyo le-ROS ngento ebizwa ngokuba yiGlutathione. Kodwa njengoko sifundile, zininzi izinto kwindawo esihlala kuzo ezityhala indlela yethu yeROS idlule kumanqanaba alindelekileyo.
I-Glutathione yinto ebalulekileyo ye-antioxidant enokukhusela iseli kumonakalo we-DNA. Ukutya kwe-Ketogenic kukunceda wenze ngakumbi i-glutathione ngokunyusa i-GCL, i-enzyme efunekayo ukudibanisa i-Glutathione. I-GCL ithathwa ngokuba "yi-enzyme yokunciphisa izinga," oku kuthetha ukuba ufumana kuphela i-glutathione eninzi njengoko unayo loo enzyme. Kwaye ke, ukutya kwe-ketogenic okwenza ngakumbi i-GCL yeyona nto ikunika i-glutathione engaphezulu kwaye liqabane elinamandla kakhulu ekunciphiseni uxinzelelo lwe-oxidative kwingqondo ye-ADHD.
isiphelo
Ngoko ke unayo. Ezi zezinye zeendlela ezininzi ukuba ukutya kwe-ketogenic kunokunceda ukunciphisa iimpawu ze-ADHD kunye ne-ADD. Njengoko ubona, ukutya kwe-ketogenic lungenelelo olunamanqanaba amaninzi.
Iphucula impilo ye-neuronal cell membrane, iphucula unxibelelwano phakathi kweeseli. Izidlo ze-Ketogenic ziphakamisa i-GABA, inceda ekuphuculeni ukungalingani kwe-glutamate / i-GABA ebonwa kulo bantu.
I-Ketones ilawula (yenza ngaphezulu) i-brain-derived neurotrophic factor (BDNF) ukwenza ukulungiswa kweeseli ze-neuronal. Khumbula, ezo receptor ze-dopamine azilungisi ngokwazo. Kodwa mhlawumbi eyona nto ibalulekileyo kukuba ummiselo kwi-BDNF unokuphucula njani inkumbulo yokusebenza kunye nokufunda kwabo bane-ADHD.
Ukutya kwe-Ketogenic akupheli apho.
Banciphisa i-neuroinflammation kunye ne-neuroprotective, eya kunciphisa uxinzelelo lwe-oxidative kwingqondo ye-ADHD.
Ukutya kwe-Ketogenic kuphucula ukusebenza kwe-mitochondrial kwaye yenze umthombo wamandla ogqwesileyo kwiindawo zobuchopho ezine-hypometabolic. Oku kuphuculwa kokuveliswa kwamandla kuzinzisa i-neuronal membranes (khumbula i-hyperpolarization?) Kwaye ivumela iiseli ukuba zisebenze ngcono. Kunokuba luncedo kakhulu kuguquko lwentetho kwi-serotonin kunye ne-dopamine receptors kunye nabathuthi ababonwa kwabo bane-ADHD kunye ne-ADD.
Ezi zizo zonke iinkalo zokuphiliswa okunokuthi kubandakanyeke kwiimpawu ze-ADHD.
Kodwa linda, ungatsho. Andinayo nje i-ADHD okanye i-ADD. Ndinemiba ye-commorbid, efana nokuphazamiseka kwengqondo kunye nengxaki yokusebenzisa kakubi iziyobisi. Oku bekungayi kundimangalisa. Xa ukusebenza kwesigqeba kuphazamisekile, nangasiphi na isizathu, abantu banenkathazo yokulawula iimvakalelo. Udinga i-lobe yangaphambili esebenza ngokupheleleyo kunye nebhalansi ye-neurotransmitter ukulawula iimvakalelo zakho. Kwaye ngenxa yokuba ukutya kwe-ketogenic kunceda ngolo hlobo lwento, akufanele kusimangalise ukuba ndinezithuba ezahlukeneyo zokuxoxa ngendlela ukutya kwe-ketogenic nako kunceda ngayo ukunyanga ixhala, ukudakumba, kunye noxinzelelo. Ukusetyenziswa kweziyobisi.
Nangona umgangatho wokunyamekela kufuneka uhlale unikezelwa kuwe, kubalulekile ukuba wazi ezinye iinketho ezisekelwe kubungqina. Ngoko unokwenza izigqibo ezizizo malunga nokubanyamekela.
Kuba unelungelo lokwazi zonke iindlela onokuziva ungcono ngazo.
Ukutya kwe ketogenic yenye yazo. Kwaye kubalulekile kum ukuba umntu anxibelelane nawe oko ukuze wenze izigqibo ezizizo malunga nonyango lwakho.
Ndifuna ukukukhuthaza ukuba ufunde ngakumbi malunga nokhetho lwakho lonyango kulo naluphi na olwam izithuba blog. Ndibhala malunga neendlela ezahlukeneyo kumanqanaba ahlukeneyo eenkcukacha onokuzifumana ziluncedo ukufunda kuhambo lwakho lwempilo.
Yabelana ngesi sithuba sebhlog okanye abanye nabahlobo kunye nosapho oluhluphekayo ngenxa yeempawu. Abantu mabazi ukuba likho ithemba.
Unokufunda ngakumbi ngam Apha. Ukuba ungathanda ukusebenzisana nam ukuncedisa kwinguqu yakho kwi-ketogenic diet, ungakwenza oko ngenkqubo ye-intanethi endiyinikezelayo.
Mna, njengesiqhelo, ndonwabe kakhulu ngethemba lokuba unokuziva ungcono.
Njengale nto ufundayo kwibhlog? Ngaba uyafuna ukufunda malunga neewebinars ezizayo, iikhosi, kunye nokubonelela ngenkxaso kunye nokusebenza nam kwiinjongo zakho zempilo? Bhalisa ngezantsi kwaye ukhuphele iSikhokelo sakho sasimahla seSondlo seBrain.
Ucaphulo
Indlela eSebenzayo yokuNqanda ukuncipha kweziyobisi. (2020, Julayi 13). NBI. https://www.nbihealth.com/a-practical-approach-to-avoiding-drug-nutrient-depletions/
Achanta, LB, & Rae, CD (2017). I-β-Hydroxybutyrate kwiBrain: I-Molekyuli enye, iiMechanism ezininzi. Uphando lwe-Neurochemical, 42(1), 35-49. https://doi.org/10.1007/s11064-016-2099-2
IAdrenaline neNoradrenaline—Nguwuphi Umahluko Yaye Zifana Ngantoni? (nd). Andréas Astier. Ibuyiselwe nge-8 kaJanuwari 2022, ukusuka https://www.andreasastier.com/blog/adrenaline-and-noradrenaline-what-are-the-differences-and-similarities
Anand, D., Colpo, GD, Zeni, G., Zeni, CP, & Teixeira, AL (2017). Ingqalelo-Intsilelo/i-Hyperactivity Disorder kunye nokudumba: Ulwazi lwangoku lusixelela ntoni? Uphononongo olucwangcisiweyo. Frontiers kwi-Psychiatry, 8, 228. https://doi.org/10.3389/fpsyt.2017.00228
Arnsten, AFT (2000). I-Genetics ye-Childhood Disorders: XVIII. I-ADHD, iSigaba 2: I-Norepinephrine Inempembelelo yokuModyuli ePhambili kwi-Prefrontal Cortical Function. Ijenali yeAmerican Academy yaBantwana noLutsha iPsychiatry, 39(9), 1201-1203. https://doi.org/10.1097/00004583-200009000-00022
Badgaiyan, RD, Sinha, S., Sajjad, M., & Wack, DS (2015). I-Tonic ye-Attenuated kunye nokukhululwa kwe-Phasic ephuculweyo ye-Dopamine kwi-Attenuated Deficit Hyperactivity Disorder. I-PLOS ONE, 10(9), e0137326. https://doi.org/10.1371/journal.pone.0137326
Banerjee, S. (2013). Ukunqongophala kweNgqwalasela ye-Hyperactivity Disorder kubantwana kunye nolutsha olufikisayo. I-BoD – Iincwadi ezikwiMfuneko.
Bedford, A., & Gong, J. (2018). Iimpembelelo zebutyrate kunye nezinto eziphuma kuyo kwimpilo yamathumbu kunye nemveliso yezilwanyana. Ukutya kwezilwanyana (Zhongguo Xu Mu Shou Yi Xue Hui), 4(2), 151-159. https://doi.org/10.1016/j.aninu.2017.08.010
Biederman, J., & Spencer, T. (1999). Ingqalelo-intsilelo/i-hyperactivity disorder (adhd) njengengxaki ye-noradrenergic. Psychiatry, 46(9), 1234-1242. https://doi.org/10.1016/S0006-3223(99)00192-4
Boison, D. (2017). Ukuqonda okutsha kwiindlela zokutya kwe-ketogenic. Uluvo lwangoku kwi-Neurology, 30(2), 187. https://doi.org/10.1097/WCO.0000000000000432
Ubuchopho bemetabolism kwimpilo, ukuguga, kunye ne-neurodegeneration. (2017). Ijenali ye-EMBO, 36(11), 1474-1492. https://doi.org/10.15252/embj.201695810
Bush, G. (2011a). I-Cingulate, Frontal, kunye ne-Parietal Cortical Dysfunction kwi-Attention-Deficit / Hyperactivity Disorder. Psychiatry, 69(12), 1160-1167. https://doi.org/10.1016/j.biopsych.2011.01.022
Bush, G. (2011b). I-Cingulate, Frontal, kunye ne-Parietal Cortical Dysfunction kwi-Attention-Deficit / Hyperactivity Disorder. Psychiatry, 69(12), 1160-1167. https://doi.org/10.1016/j.biopsych.2011.01.022
I-Carolina, i-CMM, i-PharmD, i-BCACP, i-BCGP uMncedisi weNjingalwazi ye-Pharmacy Wingate University School of Pharmacy Wingate, North. (nd). Ukuncipha kwezondlo ezibangelwa ziziyobisi: Yintoni ekufuneka iyazi iSokhemisti. Ibuyiselwe nge-6 kaJanuwari 2022, ukusuka https://www.uspharmacist.com/article/druginduced-nutrient-depletions-what-pharmacists-need-to-know
I-Cerebral glucose metabolism kwi-hyperactivity. (1991). I-New England Journal of Medicine, 324(17), 1216-1217. https://doi.org/10.1056/NEJM199104253241713
Chang, C.-H., Yu, C.-J., Du, J.-C., Chiou, H.-C., Chen, H.-C., Yang, W., Chung, M.- Y., Chen, Y.-S., Hwang, B., Mao, I.-F., & Chen, M.-L. (2018). Ukusebenzisana phakathi kokuvezwa kwe-organophosphate pesticide, uxinzelelo lwe-oxidative, kunye ne-polymorphisms yemfuza ye-dopamine receptor D4 yonyusa umngcipheko wokunqongophala / ukuphazamiseka kwengqondo ebantwaneni. UPhando lwezeNdalo, 160, 339-346. https://doi.org/10.1016/j.envres.2017.10.011
Cioffi, F., Adam, RHI, & Broersen, K. (2019). IiMechanism zeMolekyuli kunye neGenetics ye-Oxidative Stress kwi-Alzheimer's Disease. Ingxelo yeZifo ze-Alzheimer's, 72(4), 981. https://doi.org/10.3233/JAD-190863
Colucci-D'Amato, L., Speranza, L., & Volpicelli, F. (2020). I-Neurotrophic Factor BDNF, iMisebenzi yePhysiological and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer. I-International Journal ye-Molecular Sciences, 21(20), E7777. https://doi.org/10.3390/ijms21207777
ICorona, JC (2020). Indima ye-Oxidative Stress kunye ne-Neuroinflammation kwi-Attention-Deficit / Hyperactivity Disorder. Antioxidants, 9(11). https://doi.org/10.3390/antiox9111039
I-Cytokines kunye neBrain: Iimpembelelo kwi-Clinical Psychiatry | Ijenali yaseMelika yePsychiatry. (nd). Ibuyiselwe nge-8 kaJanuwari 2022, ukusuka https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.157.5.683?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Drake, J., Sultana, R., Aksenova, M., Calabrese, V., & Butterfield, DA (2003). Ukuphakama kwe-mitochondrial glutathione nge-γ-glutamylcysteine ethyl ester ikhusela i-mitochondria ngokuchasene ne-peroxynitrite-induced oxidative stress. Ijenali yoPhando lweNeuroscience, 74(6), 917-927. https://doi.org/10.1002/jnr.10810
UDunn, GA, Nigg, JT, & Sullivan, EL (2019a). I-Neuroinflammation njengomngcipheko wokunqongophala kwengxaki yokungasebenzi kakuhle. Pharmacology, Biochemistry, kunye nokuziphatha, 182, 22-34. https://doi.org/10.1016/j.pbb.2019.05.005
UDunn, GA, Nigg, JT, & Sullivan, EL (2019b). I-Neuroinflammation njengomngcipheko wokunqongophala kwengxaki yokungasebenzi kakuhle. Pharmacology Biochemistry kunye nokuziphatha, 182, 22-34. https://doi.org/10.1016/j.pbb.2019.05.005
Dvořáková, M., Sivoňová, M., Trebatická, J., Škodáček, I., Waczuliková, I., Muchová, J., & Ďuračková, Z. (2006). Isiphumo sesicatshulwa se-polyphenolic esivela kwi-pine bark, i-Pycnogenol® kwinqanaba le-glutathione kubantwana abanengxaki yokuphazamiseka kwengqondo (ADHD). Ingxelo yeRedox, 11(4), 163-172. https://doi.org/10.1179/135100006X116664
Edden, RA, Crocetti, D., Zhu, H., Gilbert, DL, & Mostofsky, SH (2012). Ukunciphisa ukugxininiswa kwe-GABA kwingqwalasela-intsilelo / ukuphazamiseka kwe-hyperactivity. Oovimba bengqondo jikelele, 69(7), 750-753. ikhonkco: I-10.1001 / archgenpsychiatry.2011.2280
Essa, MM, Subash, S., Braidy, N., Al-Adawi, S., Lim, CK, Manivasagam, T., & Guillemin, GJ (2013). Indima ye-NAD +, uxinzelelo lwe-Oxidative, kunye ne-Tryptophan Metabolism kwi-Autism Spectrum Disorders. Ijenali yeHlabathi yoPhando lweTryptophan : IJTR, 6(Ubonelelo 1), 15. https://doi.org/10.4137/IJTR.S11355
Fayed, NM, Morales, H., Torres, C., Fayed Coca, A., & Ángel Ríos, LF (2021). Ingqondo yeMagnetic Resonance Imaging kwi-Attention-Deficit/Hyperactivity Disorder (ADHD). Kwi-P. A. UGargiulo kunye noHL Mesones Arroyo (Eds.), Uhlaziyo lwePsychiatry kunye neNeuroscience: Ukusuka kwi-Epistemology ukuya kwiClinical Psychiatry - Vol. IV: Vol. IV (iphe. 623–633). Upapasho lweSpringer International. https://doi.org/10.1007/978-3-030-61721-9_44
Galic, MA, Riazi, K., & Pittman, QJ (2012). I-Cytokines kunye ne-brain excitability. Frontiers kwi-Neuroendocrinology, 33(1), 116. https://doi.org/10.1016/j.yfrne.2011.12.002
UGarcía-Rodríguez, D., & Giménez-Cassina, A. (2021). Imizimba yeKetone kwiBrain eNgaphaya kweFuel Metabolism: Ukusuka kwi-Excitability ukuya kwi-Gene Expression kunye neSibonakaliso seSeli. Frontiers kwiMoleky Neuroscience, 14. https://doi.org/10.3389/fnmol.2021.732120
I-Gene-Environment Interaction-Ushwankathelo | Izihloko zeSayensiNgqo. (nd). Ibuyiselwe nge-9 kaJanuwari 2022, ukusuka https://www.sciencedirect.com/topics/earth-and-planetary-sciences/gene-environment-interaction
Hess, JL, Akutagava-Martins, GC, Patak, JD, Glatt, SJ, & Faraone, SV (2018a). Kutheni kukho ukuba semngciphekweni okhethiweyo we-subcortical kwi-ADHD? Imikhondo evela kwi-postmortem yedatha yokubonakalisa imfuza yengqondo. I-Molecular Psychiatry, 23(8), 1787-1793. https://doi.org/10.1038/mp.2017.242
Hess, JL, Akutagava-Martins, GC, Patak, JD, Glatt, SJ, & Faraone, SV (2018b). Kutheni kukho ukuba semngciphekweni okhethiweyo we-subcortical kwi-ADHD? Imikhondo evela kwi-postmortem yedatha yokubonakalisa imfuza yengqondo. I-Molecular Psychiatry, 23(8), 1787-1793. https://doi.org/10.1038/mp.2017.242
Hou, Y., Xiong, P., Gu, X., Huang, X., Wang, M., & Wu, J. (2018). Umbutho we-Serotonin Receptors kunye neNgqaliselo yeNgqaliselo ye-Hyperactivity Disorder: Ukuphononongwa okuCwangcisiweyo kunye nohlalutyo lwe-Meta. Inzululwazi yezoNyango yangoku, 38(3), 538-551. https://doi.org/10.1007/s11596-018-1912-3
Jacintho, JD, & Kovacic, P. (2003). I-Neurotransmission kunye ne-Neurotoxicity nge-Nitric Oxide, i-Catecholamines, kunye ne-Glutamate: Imixholo edibanisayo yeentlobo ze-Oxygen eziSebenzayo kunye noTshintsho lwe-Electron. I-Medicine yamanje, 10(24), 2693-2703. https://doi.org/10.2174/0929867033456404
uYonatan. (nd). Ukunqongophala kweMicronutrient kwi-ADHD: Imvumelwano yoPhando lweHlabathi. ISOM. Ibuyiselwe nge-6 kaJanuwari 2022, ukusuka https://isom.ca/article/micronutrient-deficiencies-adhd-global-research-consensus/
UJoseph, N., Zhang-James, Y., Perl, A., & Faraone, SV (2015). Uxinzelelo lwe-Oxidative kunye ne-ADHD: Uhlalutyo lwe-Meta. Ijenali yeZiphazamiso zeNgqwalasela, 19(11), 915-924. https://doi.org/10.1177/1087054713510354
Kapoor, D., Garg, D., & Sharma, S. (2021). Indima ekhulayo ye-Ketogenic Dietary Therapies ngaphaya kwe-Epilepsy kwi-Child Neurology. I-Annals ye-Indian Academy ye-Neurology, 24(4), 470. https://doi.org/10.4103/aian.AIAN_20_21
Kautzky, A., Vanicek, T., Philippe, C., Kranz, GS, Wadsak, W., Mitterhauser, M., Hartmann, A., Hahn, A., Hacker, M., Rujescu, D., Kasper , S., & Lanzenberger, R. (2020). Ukuhlelwa komatshini wokufunda we-ADHD kunye ne-HC ngedatha ye-multimodal serotonergic. Psychiatry yokuguqulela, 10(1), 1-9. https://doi.org/10.1038/s41398-020-0781-2
Kerekes, N., Sanchéz-Pérez, AM, & Landry, M. (2021). I-Neuroinflammation njengekhonkco elinokwenzeka phakathi kwengqwalasela-intsilelo / i-hyperactivity disorder (ADHD) kunye neentlungu. Unyango lwezonyango, 157, 110717. https://doi.org/10.1016/j.mehy.2021.110717
Khansari, N., Shakiba, Y., & Mahmoudi, M. (2009). Ukuvuvukala okungapheliyo kunye noxinzelelo lwe-oxidative njengonobangela omkhulu wezifo ezinxulumene neminyaka kunye nomhlaza. Amalungelo awodwa omenzi wechiza akutsha nje kuKudumba kunye nokuFunyaniswa kwechiza lokwala, 3(1), 73-80. https://doi.org/10.2174/187221309787158371
UKim, SW, Marosi, K., & Mattson, M. (2017). I-Ketone beta-hydroxybutyrate up-regulates BDNF expression through NF-κB as an adaptive response against ROS, enokuphucula i-neuronal bioenergetics kunye nokuphucula i-neuroprotection (P3.090). Neurology, 88(16 Isongezelelo). https://n.neurology.org/content/88/16_Supplement/P3.090
Kovacic, P., & Weston, W. (nd). Ingqalelo-intsilelo-ingxaki yokungakhathali-indlela yokudibanisa ebandakanya unyango lwe-antioxidant: i-Phenolics, iintlobo zeoksijini esebenzayo, kunye noxinzelelo lwe-oxidative.. 6.
Kovács, Z., D'Agostino, DP, Diamond, D., Kindy, MS, Rogers, C., & Ari, C. (2019a). Amandla oNyango lwe-Exogenous Ketone Supplement eyenziwe yi-Ketosis kuNyango lwe-Psychiatric Disorders: Uphononongo lweeNcwadi zangoku. Frontiers kwi-Psychiatry, 10, 363. https://doi.org/10.3389/fpsyt.2019.00363
Kovács, Z., D'Agostino, DP, Diamond, D., Kindy, MS, Rogers, C., & Ari, C. (2019b). Amandla oNyango lwe-Exogenous Ketone Supplement eyenziwe yi-Ketosis kuNyango lwe-Psychiatric Disorders: Uphononongo lweeNcwadi zangoku. Frontiers kwi-Psychiatry, 10, 363. https://doi.org/10.3389/fpsyt.2019.00363
Kronfol, Z., & Remick, DG (2000). I-Cytokines kunye neBrain: Iimpembelelo kwi-Clinical Psychiatry. I-American Journal ye-Psychiatry, 157(5), 683-694. https://doi.org/10.1176/appi.ajp.157.5.683
Kul, M., Unal, F., Kandemir, H., Sarkarati, B., Kilinc, K., & Kandemir, SB (2015). Uvavanyo lweMetabolism ye-Oxidative kuMntwana kunye nezigulane ezifikisayo ezineNgqwalaselo ye-Attention Deficit Hyperactivity Disorder. UPhando lweNgqondo, 12(3), 361-366. https://doi.org/10.4306/pi.2015.12.3.361
Lee, YH, & Ingoma, GG (2018). Uhlalutyo lwe-Meta ye-Case-Control kunye neMibutho esekwe kwiNtsapho phakathi kwe-5-HTTLPR L / S Polymorphism kunye nokuSebenza kwi-ADHD. Ijenali yeZiphazamiso zeNgqwalasela, 22(9), 901-908. https://doi.org/10.1177/1087054715587940
Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., Zhu, L.- Q., & Wu, J. (2015a). IPhysiology yeBDNF kunye nobudlelwane bayo kunye ne-ADHD. I-mourobiology yeMolekyuli, 52(3), 1467-1476. https://doi.org/10.1007/s12035-014-8956-6
Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., Zhu, L.- Q., & Wu, J. (2015b). IPhysiology yeBDNF kunye nobudlelwane bayo kunye ne-ADHD. I-mourobiology yeMolekyuli, 52(3), 1467-1476. https://doi.org/10.1007/s12035-014-8956-6
U-Liu, H., Wang, J., Yena, T., Becker, S., Zhang, G., Li, D., & Ma, X. (2018). I-Butyrate: Ikrele elintlangothi-mbini leMpilo? Inkqubela phambili kwisondlo (iBethesda, Md.), 9(1), 21-29. https://doi.org/10.1093/advances/nmx009
Lussier, DM, Woolf, EC, Johnson, JL, Brooks, KS, Blattman, JN, & Scheck, AC (2016). Ukungakhuseleki okuphuculweyo kwimodeli yegundane ye-glioma enobungozi ixutywe ngokutya kwe-ketogenic yonyango. Umhlaza weBMC, 16(1), 310. https://doi.org/10.1186/s12885-016-2337-7
Maltezos, S., Hoorder, J., Coghlan, S., Skirrow, C., O'Gorman, R., Lavender, TJ, Mendez, MA, Mehta, M., Daly, E., Xenitidis, K., Paliokosta, E., Spain, D., Pitts, M., Asherson, P., Lythgoe, DJ, Barker, GJ, & Murphy, DG (2014). I-Glutamate/glutamine kunye nengqibelelo ye-neuronal kubantu abadala abane-ADHD: isifundo se-proton MRS. Psychiatry yokuguqulela, 4(3), e373-e373. https://doi.org/10.1038/tp.2014.11
Mamiya, PC, Arnett, AB, & Stein, MA (2021a). Ukhathalelo lwezonyango oluchanekileyo kwi-ADHD: Ityala le-Neural Excitation kunye nokuThintelwa. Sciences zeBongo, 11(1), 91. https://doi.org/10.3390/brainsci11010091
Mamiya, PC, Arnett, AB, & Stein, MA (2021b). Ukhathalelo lwezonyango oluchanekileyo kwi-ADHD: Ityala le-Neural Excitation kunye nokuThintelwa. Sciences zeBongo, 11(1), 91. https://doi.org/10.3390/brainsci11010091
Martins, MR, Reinke, A., Petronilho, FC, Gomes, KM, Dal-Pizzol, F., & Quevedo, J. (2006). Unyango lweMethylphenidate lubangela uxinzelelo lwe-oxidative kwingqondo encinci yegundane. Uphando lobuchopho, 1078(1), 189-197. https://doi.org/10.1016/j.brainres.2006.01.004
Merker, S., Reif, A., Ziegler, GC, Weber, H., Mayer, U., Ehlis, A.-C., Conzelmann, A., Johansson, S., Müller-Reible, C., Nanda , I., Haaf, T., Ullmann, R., Romanos, M., Fallgatter, AJ, Pauli, P., Strekalova, T., Jansch, C., Vasquez, AA, Haavik, J., … Lesch, K.-P. (2017a). I-SLC2A3 i-polymorphism eyodwa ye-nucleotide kunye nokuphindaphinda kunempembelelo ekusetyenzweni kwengqondo kunye nomngcipheko othe ngqo wabemi wokungabikho kwengqwalasela / ukuphazamiseka kwengqondo. I-Journal ye-Child Psychology kunye ne-Psychiatry, 58(7), 798-809. https://doi.org/10.1111/jcpp.12702
Merker, S., Reif, A., Ziegler, GC, Weber, H., Mayer, U., Ehlis, A.-C., Conzelmann, A., Johansson, S., Müller-Reible, C., Nanda , I., Haaf, T., Ullmann, R., Romanos, M., Fallgatter, AJ, Pauli, P., Strekalova, T., Jansch, C., Vasquez, AA, Haavik, J., … Lesch, K.-P. (2017b). I-SLC2A3 i-polymorphism eyodwa ye-nucleotide kunye nokuphindaphinda kunempembelelo ekusetyenzweni kwengqondo kunye nomngcipheko othe ngqo wabemi wokungabikho kwengqwalasela / ukuphazamiseka kwengqondo. Ijenali ye Psychology yaBantwana kunye nonyango lwengqondo, kunye noqeqesho oluhlangeneyo, 58(7), 798-809. https://doi.org/10.1111/jcpp.12702
Millenet, SK, Nees, F., Heintz, S., Bach, C., Frank, J., Vollstädt-Klein, S., Bokde, A., Bromberg, U., Büchel, C., Quinlan, EB, Desrivières, S., Fröhner, J., Flor, H., Frouin, V., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Lemaire, H., … Hohmann, S. (2018). I-COMT Val158Met Polymorphism kunye nokukhubazeka kweNtlalo ngokuSebenzayo kuchaphazela iNgqalelo-Intsilelo yeempawu zokuSebenza kwiNtsana esempilweni. Imida kwiGenetics, 9, 284. https://doi.org/10.3389/fgene.2018.00284
Millichap, J. (1990). I-Cerebral Glucose Metabolism kunye ne-ADHD. IiNgcaciso zeNeurology yabantwana, 4(11), 83-84. https://doi.org/10.15844/pedneurbriefs-4-11-4
Murphy, P., & Burnham, WM (2006). Ukutya kwe-ketogenic kubangela ukuhla okubuyela umva kwinqanaba lomsebenzi kwiigundane ze-Long-Evans. I-Neurology yoMfuniselo, 201(1), 84-89. https://doi.org/10.1016/j.expneurol.2006.03.024
I-Neuroinflammation njengekhonkco elinokwenzeka phakathi kwengqwalasela-intsilelo / i-hyperactivity disorder (ADHD) kunye neentlungu | Elsevier Enhanced Reader. (nd). https://doi.org/10.1016/j.mehy.2021.110717
Uphando olutsha kwi-Keto Diet kunye ne-GLUT1 Deficiency Syndrome. (2020, Februwari 19). Ketogenic.Com. https://ketogenic.com/glut1-deficiency-syndrome/
UNikolaidis, A., & Grey, JR (2010). I-ADHD kunye ne-DRD4 exon III 7-i-polymorphism ephindaphindayo: Uhlalutyo lwemeta lwamazwe ngamazwe. I-Social Cognitive and Affective Neuroscience, 5(2-3), 188-193. https://doi.org/10.1093/scan/nsp049
Norwitz, NG, Hu, MT, & Clarke, K. (2019). Iinkqubo apho uMzimba weKetone D-β-Hydroxybutyrate unokuphucula iiPathologies zeSelula ezininzi ze-Parkinson's Disease. Imida kwiZondlo, 6, 63. https://doi.org/10.3389/fnut.2019.00063
Ukuncipha kwezondlo. (nd). Iziko lempilo yeBioMed. Ibuyiselwe nge-6 kaJanuwari 2022, ukusuka https://wellnessbiomed.com/pages/nutrient-depletion
UPaoli, A. (2020). Isifundo esilingwayo: Ukutya kwe-Ketogenic njengoKhuseleko ngexesha losulelo lwe-SARS-CoV-2 (Ubhaliso lweTyala lweKlinikhi No. NCT04615975). clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04615975
Peng, W., Tan, C., Mo, L., Jiang, J., Zhou, W., Du, J., Zhou, X., Liu, X., & Chen, L. (2021). I-Glucose transporter 3 kwi-neuronal glucose metabolism: Impilo kunye nezifo. Metabolism, 123, 154869. https://doi.org/10.1016/j.metabol.2021.154869
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017). Uxinzelelo lwe-Oxidative: Iingozi kunye neeNzuzo kwiMpilo yoLuntu. Unyango lwe-Oxidative kunye nokuPhila ixesha elide, 2017. https://doi.org/10.1155/2017/8416763
UPizzorno, J. (2014). I-Mitochondria-Isiseko soBomi kunye neMpilo. I-Integrative Medicine: Ijenali yeClinikhi, 13(2), 8.
Purkayastha, P., Malapati, A., Yogeeswari, P., & Sriram, D. (2015). Uphononongo kwiGABA/Glutamate Indlela yoNyango loNyango lwe-ASD kunye ne-ADHD. I-Medicine yamanje, 22(15), 1850-1859.
Ubeka, NA, Ryan, M., Oeltzschner, G., Horska, A., Edden, RAE, & Mahone, EM (2020). Ukunciphisa i-GABA yokubulala kubantwana abangasetyenziswanga abane-ADHD kwi-7T. UPhando lwezePsychational: Neuroimaging, 301, 111082. https://doi.org/10.1016/j.pscychresns.2020.111082
Réus, GZ, Scaini, G., Titus, SE, Furlanetto, CB, Wessler, LB, Ferreira, GK, Gonçalves, CL, Jeremias, GC, Quevedo, J., & Streck, EL (2015). I-Methylphenidate yonyusa i-glucose kwingqondo yeegundane ezincinci kunye nabantu abadala. Iingxelo ze-Pharmacological, 67(5), 1033-1040. https://doi.org/10.1016/j.pharep.2015.03.005
Saccaro, LF, Schilliger, Z., Perroud, N., & Piguet, C. (2021). Ukuvutha, ukuxhalaba, kunye noxinzelelo kwiNgqwalasela-Intsilelo / i-Hyperactivity Disorder. Iintsholongwane, 9(10), 1313. https://doi.org/10.3390/biomedicines9101313
Schmitz, F., Silveira, J., Venturin, G., Greggio, S., Schu, G., Zimmer, E., Dacosta, J., & Wyse, A. (2021). Ubungqina bokuba unyango lwe-Methylphenidate lukhupha iNgxaki-efana nokuziphatha nge-Glucose Hypometabolism kunye nokuphazamiseka kwe-Orbitofrontal Cortex Metabolic Networks. Uphando lweNeurotoxicity, 39. https://doi.org/10.1007/s12640-021-00444-9
Sengupta, SM, Grizenko, N., Thakur, GA, Bellingham, J., DeGuzman, R., Robinson, S., TerStepanian, M., Poloskia, A., Shaheen, SM, Fortier, M.-E., Choudhry, Z., & Joober, R. (2012). Unxulumano olwahlukileyo phakathi kohlobo lwe-norepinephrine transporter gene kunye ne-ADHD: Indima yesini kunye ne-subtype. Ijenali yePsychiatry & Neuroscience: JPN, 37(2), 129. https://doi.org/10.1503/jpn.110073
Seyedi, M., Gholami, F., Samadi, M., Djalali, M., Effatpanah, M., Yekaninejad, MS, Hashemi, R., Abdolahi, M., Chamari, M., & Honarvar, NM (2019) ). Umphumo we-Vitamin D3 yoMxholo kwi-Serum BDNF, i-Dopamine, kunye ne-Serotonin kubantwana abaneNgqaliselo-Intsilelo / i-Hyperactivity Disorder. I-CNS kunye ne-Neurological Disorders-IiThagethi zeDrug-CNS & Neurological Disorders), 18(6), 496-501. https://doi.org/10.2174/1871527318666190703103709
Sheehan, K., Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M., Gill, M., & Hawi, Z. (2005). I-Tryptophan hydroxylase 2 (TPH2) iintlobo zemfuza ezinxulumene ne-ADHD. I-Molecular Psychiatry, 10(10), 944-949. https://doi.org/10.1038/sj.mp.4001698
Sigurdardottir, HL, Kranz, GS, Rami-Mark, C., James, GM, Vanicek, T., Gryglewski, G., Kautzky, A., Hienert, M., Traub-Weidinger, T., Mitterhauser, M. , Wadsak, W., Hacker, M., Rujescu, D., Kasper, S., & Lanzenberger, R. (2016). Iziphumo ze-norepinephrine transporter gene variants kwi-NET ebophelelayo kwi-ADHD kunye nolawulo olunempilo oluphandwe yi-PET. Imephu yeBongo yoBuntu, 37(3), 884-895. https://doi.org/10.1002/hbm.23071
Ukusa, RM, van de Wouw, M., Clarke, G., Stanton, C., Dinan, TG, & Cryan, JF (2016). I-neuropharmacology ye-butyrate: Isonka kunye nebhotolo ye-microbiota-gut-brain axis? I-Neurochemistry International, 99, 110-132. https://doi.org/10.1016/j.neuint.2016.06.011
Striatum-Ushwankathelo | Izihloko zeSayensiNgqo. (nd). Ibuyiselwe nge-7 kaJanuwari 2022, ukusuka https://www.sciencedirect.com/topics/psychology/striatum
Stuart, CA, Ross, IR, Howell, MEA, McCurry, MP, Wood, TG, Ceci, JD, Kennel, SJ, & Wall, J. (2011). I-Brain Glucose Transporter (Glut3) i-Haploinsufficiency ayikuphazamisi iMouse Brain Brain Glucose Uptake. Uphando lobuchopho, 1384, 15. https://doi.org/10.1016/j.brainres.2011.02.014
I-Neuropharmacology ye-Ketogenic Diet kwi-DuckDuckGo. (nd). Ibuyiselwe nge-8 kaJanuwari 2022, ukusuka https://duckduckgo.com/?q=The+Neuropharmacology+of+the+Ketogenic+Diet&atb=v283-1&ia=web
Ułamek-Kozioł, M., Czuczwar, SJ, Januszewski, S., & Pluta, R. (2019). Ukutya kwe-Ketogenic kunye neSithuthwane. Amanzi, 11(10). https://doi.org/10.3390/nu11102510
Vergara, RC, Jaramillo-Riveri, S., Luarte, A., Moënne-Loccoz, C., Fuentes, R., Couve, A., & Maldonado, PE (2019). I-Energy Homeostasis Principle: I-Neuronal Energy Regulation Drives Local Network Dynamics Generating Behaviour. Imida kwiComputerational Neuroscience, 13. https://doi.org/10.3389/fncom.2019.00049
Ukutya okune-carbohydrate ephantsi kakhulu konyusa ukunganyangeki kwe-T-cell yomntu ngokusebenzisa i-immunometabolic reprogramming. (2021). Unyango lweMolekyuli ye-EMBO, 13(8), e14323. https://doi.org/10.15252/emmm.202114323
Yintoni i-xenobiotics kunye nemizekelo yazo? (nd). Ibuyiselwe nge-9 kaJanuwari 2022, ukusuka https://psichologyanswers.com/library/lecture/read/98518-what-are-xenobiotics-and-their-examples
Wiers, CE, Lohoff, FW, Lee, J., Muench, C., Freeman, C., Zehra, A., Marenco, S., Lipska, BK, Auluck, PK, Feng, N., Sun, H. , Goldman, D., Swanson, JM, Wang, G.-J., & Volkow, ND (2018). I-Methylation ye-dopamine transporter gene egazini inyanyaniswa nokufumaneka kwesithuthi se-striatal dopamine kwi-ADHD: isifundo sokuqala. I-European Journal ye-Neuroscience, 48(3), 1884-1895. https://doi.org/10.1111/ejn.14067
Włodarczyk, A., Wiglusz, MS, & Cubała, WJ (2018). Ukutya kwe-Ketogenic kwi-schizophrenia: indlela yokutya yonyango lwe-antipsychotic. Unyango lwezonyango, 118, 74-77. https://doi.org/10.1016/j.mehy.2018.06.022
Xu, W., Gao, L., Li, T., Shao, A., & Zhang, J. (2018). Indima ye-Neuroprotective ye-Agmatine kwiZifo ze-Neurological. I-Neuropharmacology yangoku, 16(9), 1296. https://doi.org/10.2174/1570159X15666170808120633
Yokokura, M., Takebasashi, K., Takao, A., Nakaizumi, K., Yoshikawa, E., Futatsubashi, M., Suzuki, K., Nakamura, K., Yamasue, H., & Ouchi, Y. (2021). Kwi-vivo imaging ye-dopamine i-D1 receptor kunye ne-microglia esebenzayo kwingqwalasela-intsilelo/ingxaki yokungasebenzi kakuhle: isifundo se-positron emission tomography. I-Molecular Psychiatry, 26(9), 4958-4967. https://doi.org/10.1038/s41380-020-0784-7
Zametkin, AJ, Nordahl, TE, Gross, M., King, AC, Semple, WE, Rumsey, J., Hamburger, S., & Cohen, RM (1990). I-Cerebral glucose metabolism kubantu abadala abane-hyperactivity yokuqala komntwana. I-New England Journal of Medicine, 323(20), 1361-1366. https://doi.org/10.1056/NEJM199011153232001
Zhang, S., Wu, D., Xu, Q., Wena, L., Zhu, J., Wang, J., Liu, Z., Yang, L., Tong, M., Hong, Q., & Chi, X. (2021). Isiphumo esikhuselayo kunye nendlela enokubakho ye-NRXN1 ekufundeni nakwinkumbulo kwiimodeli zeempuku ze-ADHD. I-Neurology yoMfuniselo, 344, 113806. https://doi.org/10.1016/j.expneurol.2021.113806
Zhou, R., Wang, J., Han, X., Ma, B., Yuan, H., & Song, Y. (2019). I-Baicalin ilawula inkqubo ye-dopamine ukulawula iimpawu eziphambili ze-ADHD. Brain Molecular, 12(1), 11. https://doi.org/10.1186/s13041-019-0428-5
(Nd). Ibuyiselwe nge-7 kaJanuwari 2022, ukusuka https://www.mind-diagnostics.org/blog/adhd/finding-the-connection-between-dopamine-and-adhd
3 Comments